Join us at Medica 2023
We are pleased to inform you about our participation at Medica, the prominent trade fair for the medical industry, scheduled from November 13th to November 16th in Düsseldorf.
Don’t miss this opportunity to connect with us and discover the latest advancements in medical RF technology. You can find us at the Belgium pavilion in Hall 15, Booth C16. Looking forward to meeting you!
Available from today, this all-inclusive Fistura Pack is a complete set of supplies for the treatment of anal fistulas.
A French prospective multicentre study assessed RFA (Rafaelo®) in 129 outpatients with grade II–III haemorrhoids with a 1 year follow up.
16 Centres participated in the research. RFA was performed in the operating room under locoregional or general anaesthesia. Primary endpoint was the evolution of a quality-of-life score adapted to the haemorrhoid pathology (HEMO-FISS-QoL) 3 months after surgery. Secondary endpoints were evolution of symptoms, complications, postoperative pain and medical leave.
The researchers concluded that RFA is associated with an improvement in quality of life and symptoms with a good safety profile. As expected for minimally invasive surgery, postoperative pain is minor with short medical leave. They pointed out that regarding average operating times, RFA is more rapid (15 min) than other techniques.
The U.S. Food and Drug Administration (FDA) has approved the HPR45i electrosurgical electrode to conduct radiofrequency (RF) current for coagulation from the RF electrosurgical generator MedRF4000® to target soft tissue in a broad range of surgical procedures.